Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval

Opzelura Is First Topical JAK Inhibitor Approved In US

 
• By Sten Stovall
  
Ruxolitinib Cream Approved With JAK-Class Boxed Warnings • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip